FAT1 and neoplasm: FAT1 was prioritized as a top candidate of clinical relevance, as inactivating mutations in FAT1 were highly recurrent (~10%) in the TRACERx 421 cohort (comprising 421 patients and 1,644 tumour regions), with a notable proportion of FAT1 mutations occurring early before WGD (Fig. 1g and Supplementary Fig. 5a–c).